CROI 2014: Antiretrovirals Panel
A discussion of the highlights of antiretroviral presentations at CROI, the most interesting being long acting therapies, which have the potential to successfully treat people with adherence issues. A second study comparing raltegravir to two protease inhibitors demonstrated lower side effects with a combination that has less long term side effects. In general presentations showed the direction the technology is moving in is toward better, easier to take, less frequently dosed medications.
Daniel R. Kuritzkes
Chief, Division of Infectious Disease
Brigham and Women’s Hospital